Abstract
Isoniazid preventive therapy (IPT) is recommended in patients on antiretroviral treatment. Isoniazid (INH) inhibits CYP3A4, which metabolises nevirapine (NVP). Administration of INH may cause higher NVP concentrations and toxicity. We studied the effect of INH on NVP concentrations in 21 patients randomised to either placebo (n = 13) or INH (n = 8) in an ongoing trial of IPT in patients on ART. INH was associated with a 24% increase in median NVP area under the plasma concentration-time curve for the 12 h dosing interval, which was not statistically significant (P = 0.66).
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / pharmacokinetics*
-
Antitubercular Agents / administration & dosage*
-
Area Under Curve
-
Biotransformation
-
Cytochrome P-450 CYP3A / metabolism
-
Cytochrome P-450 CYP3A Inhibitors*
-
Drug Administration Schedule
-
Drug Interactions
-
Drug Monitoring
-
Enzyme Inhibitors / administration & dosage*
-
Female
-
HIV Infections / drug therapy*
-
Humans
-
Isoniazid / administration & dosage*
-
Male
-
Nevirapine / administration & dosage
-
Nevirapine / blood
-
Nevirapine / pharmacokinetics*
-
South Africa
Substances
-
Anti-HIV Agents
-
Antitubercular Agents
-
Cytochrome P-450 CYP3A Inhibitors
-
Enzyme Inhibitors
-
Nevirapine
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human
-
Isoniazid